

# NEUROMICS

## Kappa Opioid Receptor Data Sheet

---

<b>Catalog Number:</b>	RA10103T	<b>Host:</b>	Rabbit
<b>Product Type:</b>	Polyclonal antiserum	<b>Species Reactivity:</b>	Human
<b>Immunogen Sequence:</b>	DPAYLRDIDGMNKPV Corresponding to residues 366-380 of the carboxy-terminus of human kappa opioid	<b>Format:</b>	Whole Serum (with 0.05% sodium azide) Sent in liquid form
<b>Applications:</b>	Immunocytochemistry 1:5 – 10,000 Dilutions listed only as a recommendation. Optimal dilution should be determined by investigator.		
<b>Storage:</b>	Store frozen. Aliquot as undiluted serum and immediately place at -20°C. Serum may have become trapped in top of vial during shipping. Centrifugation of vial is recommended before opening. Stable for at least 6 months at -20°C. Repeated freeze/thaw cycles compromise the integrity of the antiserum.		
<b>References:</b>	Mansson, E., Bare, L., and Yang, D. (1994). <i>Isolation of a human kappa opioid receptor cDNA from placenta</i> . <i>Biochem Biophys Res Commun</i> 202, 1431-7.		

---

### Application Notes

**Immunocytochemistry:** Kappa opioid receptor transfected cells were processed for indirect immunofluorescence. Media was removed and cells were gently washed 3 times with serum-free media. Media was removed and cells were gently washed 3 times with serum-free media. Following fixation procedure, cells were processed for indirect immunofluorescence as described above.




Image:  
HEK293  
transiently  
transfected  
with KOR.  
Specific  
signal is red,  
nuclei -  
stained with  
DAPI (blue).

*Note:* Sodium azide (NaN<sub>3</sub>) interferes with peroxidase reactions and should not be used with peroxidase methodologies. If sodium azide is present in any steps of the staining procedure, the tissue should thoroughly be rinsed with sodium azide-free buffer before performing the peroxidase reaction.

### FOR RESEARCH USE ONLY

NEUROMICS REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.

Please visit our website for complete information on protocols, buffers and solutions @ [www.neuromics.com](http://www.neuromics.com)

Neuromics Antibodies • 5325 West 74<sup>th</sup> Street, Suite 8 • Edina, MN 55439  
phone 866-350-1500 • fax 612-677-3976 • e-mail [pshuster@neuromics1.com](mailto:pshuster@neuromics1.com)